Acne
Conditions
Interventions
Experimental group:35% complex acid treatment with 15% azelaic acid gel at home
Control group:Treatment with 35% complex acid excipients (excluding salicylic acid and AHAs) was performed, along with azelaic acid at home
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Patients with mild-to-moderate acne diagnosed according to the Chinese Acne Treatment Guidelines (2019 Edition) with the following facial features: (1) 20 - 50 inflammatory skin lesions (papules, pustules); (2) 30 - 100 non-inflammatory lesions (open and closed comedones); (3) No more than 2 facial nodules; IGA score is mild (2 points) or moderate (3 points); 2) Age 18 to 60 years old; 3) The patient voluntarily participates in this clinical study and signs a written informed consent form. And to comply with lifestyle precautions throughout the study: willing to use only the cleanser and moisturizer provided by this study without any medication, and not to use other acne medications, etc.; Do not use cosmetics such as foundation, barrier and makeup; Strenuous exercise should be avoided for 72 hours prior to the planned study visit.
Exclusion criteria
Exclusion criteria: 1) Facial suffering from other skin diseases, such as melasma, freckles and seborrheic dermatitis, which may affect the judgment of the test results; 2) Those who are allergic to the test product or have a highly allergic constitution; 3) Pregnant, pregnant, or lactating patients; 4) Laboratory test results of liver function and renal function are judged by doctors to be clinically significant abnormalities; 5) Patients with secondary acne, such as occupational acne and acne caused by sebaceous steroids; 6) Patients with oral antibiotics, glucocorticoids, spironolactone and other anti-androgens and other oral drugs for acne within 4 weeks before the test; or patients who have used salicylic acid, fruit acid, azelaic acid or physical therapy for acne within 2 weeks; 7) Those who took oral retinoids within 3 months before the test; 8) Facial plastic surgery, grinding, laser, injection treatment and other treatments in the 2 months before the trial; 9) Patients with immunodeficiency diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in PAHPI index of PIE and PIH lesions before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lesion reduction rate = (total number of lesions before treatment - total number of lesions after treatment) / total number of lesions before treatment ×100%;Total effective rate = (number of cases of significant improvement + number of cases of regression) / total number of cases × 100%.;Investigator Global Assessement, IGA score;;Physician Global Assessment (PGA);Investigator's subjective score of erythema;Subjective score of the investigator's color pigmentation;Dermoscopy;Subject's Dermatology Life Quality Index Assessment (DLQI);Subject satisfaction evaluation;FACIAL VISIA PHOTOGRAPHED;Non-invasive skin physiological indicators: L*a*b value (melanin, heme), ITA value, skin water content, TEWL, oil detection; | — |
Countries
China
Contacts
Public ContactXian Jiang
West China Hospital of Sichuan University
Outcome results
None listed